EZH2/PRC2 methylates H3K27 and leads to transcriptional silence of target genes in multiple subtypes of cancers, including ovarian cancer, breast cancer, PC, T-cell ALL and non-Hodgkin lymphoma [119–128]. Here, EZH2 is linked to ovarian carcinoma.